• 1. Exclusive self-aligned β-phase PVDF films with abnormal piezoelectric coefficient prepared via phase inversion?
  N. Soin,D. Boyer,K. Prashanthi,S. Sharma,A. A. Narasimulu,J. Luo,T. H. Shah,E. Siores,T. Thundat Chem. Commun., 2015,51, 8257-8260
• 2. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 3. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 4. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 5. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Fluorobenzenes

Introduction to 2-(3-fluoro-4-methylphenyl)acetic acid (CAS No. 261951-74-0)

2-(3-fluoro-4-methylphenyl)acetic acid, identified by the Chemical Abstracts Service Number (CAS No.) 261951-74-0, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the class of substituted benzoic acids, characterized by its unique structural features that include a fluorine atom at the 3-position and a methyl group at the 4-position of the phenyl ring, coupled with an acetic acid moiety at the other end. The presence of these functional groups imparts distinct chemical and biological properties, making it a valuable scaffold for further derivatization and exploration in drug discovery.

The fluorine substituent in 2-(3-fluoro-4-methylphenyl)acetic acid plays a crucial role in modulating its pharmacokinetic and pharmacodynamic properties. Fluorine atoms are well-known for their ability to enhance metabolic stability, improve binding affinity to biological targets, and influence the overall bioavailability of pharmaceutical compounds. In recent years, the incorporation of fluorine into drug molecules has been extensively studied due to its ability to fine-tune electronic and steric effects, thereby optimizing drug efficacy and selectivity. The specific positioning of the fluorine atom at the 3-position of the phenyl ring in this compound suggests potential interactions with enzymes or receptors that are sensitive to fluorine-containing structures.

Similarly, the methyl group at the 4-position contributes to the compound's overall physicochemical properties, including lipophilicity and solubility. The presence of this substituent can influence how the molecule interacts with biological membranes and cellular components, which is critical for drug absorption, distribution, metabolism, and excretion (ADME) profiles. The combination of a fluoro-substituted phenyl ring and an acetic acid moiety creates a versatile platform for designing molecules with enhanced pharmacological activity. This structural motif has been explored in various therapeutic areas, including oncology, inflammation, and central nervous system (CNS) disorders.

In recent years, 2-(3-fluoro-4-methylphenyl)acetic acid has been investigated as a potential lead compound for developing novel therapeutic agents. Its unique structural features make it an attractive candidate for further chemical modification to improve pharmacological properties. For instance, researchers have explored derivatives of this compound as inhibitors of specific enzymes involved in cancer progression. The fluorine atom's ability to enhance binding interactions with target proteins has been leveraged to design molecules with improved potency and selectivity against kinases and other enzymes implicated in tumor growth.

Moreover, studies have indicated that 2-(3-fluoro-4-methylphenyl)acetic acid exhibits anti-inflammatory properties by modulating pathways associated with cytokine production and immune cell function. The acetic acid moiety can serve as a hinge region for binding to biological targets, while the fluorine and methyl substituents fine-tune interactions for optimal efficacy. Preclinical studies have demonstrated promising results in models of inflammation, suggesting that this compound or its derivatives could be developed into novel anti-inflammatory therapies.

The synthesis of 2-(3-fluoro-4-methylphenyl)acetic acid involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Common synthetic routes include Friedel-Crafts alkylation followed by fluorination and carboxylation steps. Advanced techniques such as palladium-catalyzed cross-coupling reactions have also been employed to introduce the desired substituents efficiently. The synthesis process must be carefully optimized to minimize side reactions and byproduct formation, ensuring that the final product meets pharmaceutical-grade standards.

The chemical stability of 2-(3-fluoro-4-methylphenyl)acetic acid is another critical consideration in its development as a pharmaceutical agent. Fluorinated aromatic compounds can exhibit varying degrees of sensitivity to hydrolysis or oxidation under certain conditions. Therefore, storage conditions must be carefully controlled to maintain stability throughout the supply chain. Analytical techniques such as high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry (MS) are routinely employed to confirm purity and assess stability profiles.

From a regulatory perspective, 2-(3-fluoro-4-methylphenyl)acetic acid must undergo rigorous testing to meet safety and efficacy standards before being considered for clinical use. Preclinical studies involving cell culture assays, animal models, and pharmacokinetic evaluations provide essential data on its biological activity and potential toxicity. These studies are crucial for identifying optimal dosing regimens and understanding potential side effects before human trials are initiated.

In conclusion,2-(3-fluoro-4-methylphenyl)acetic acid (CAS No. 261951-74-0) is a structurally interesting compound with significant potential in pharmaceutical research. Its unique combination of functional groups makes it a valuable scaffold for developing novel therapeutic agents with enhanced pharmacological properties. Ongoing research continues to explore its applications in various therapeutic areas, highlighting its importance as a building block for future drug discovery efforts.

• 85068-27-5((2,5-Difluorophenyl)acetic Acid)
• 203314-27-6(2-Fluoro-5-methylphenylacetic Acid)
• 1355247-84-5(3-(3-Fluoro-4-methylphenyl)phenylacetic acid)
• 145689-41-4(2-(2,3-Difluorophenyl)acetic acid)
• 518070-28-5(2-(2-fluoro-4-methylphenyl)acetic acid)
• 451-82-1(2-Fluorophenylacetic acid)
• 886762-65-8((2-Fluoro-3-methylphenyl)acetic acid)
• 1365272-72-5(4-(3-Fluoro-4-methylphenyl)phenylacetic Acid)
• 500912-16-3(2-(3-Fluoro-2-methylphenyl)acetic acid)
• 1000520-92-2(2-(4-Fluoro-3-methylphenyl)acetic acid)